Fig. 4.

PCBP1 depletion increases tumor ferroptosis sensitivity in vivo.

(A–C) Representative images (A), in vivo growth (B), and weights (C) of tumors treated with or without daily intraperitoneal injection of SAS (250 mg/kg) for 20 days. Each group included seven mice. (D) Cellular iron contents were measured using iron assay kits in tumor tissues. (E–F) Malondialdehyde (MDA) assays (E) and oil red staining (F) in tumor tissues. (G) Immunoblotting of PCBP1, ACSL4, ALOX15, NCOA4, FTH1, 4-HNE, and PTGS2 in HN12 tumors. The error bars represent standard errors from tumors of different groups. ns; no significance, *P < 0.05, **P < 0.01, ***P < 0.001 between different groups. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)